IceCure Medical

The choice of cryoablation for the minimally invasive destruction of benign and cancerous tumors

Health Tech & Life Sciences
Public on TASE on Feb 2011
Public on NASDAQ on Aug 2021

Company Overview

Snapshot

Founded in January 2006, IceCure Medical operates with 51–200 employees and has raised a total of $71.53 million across 12 funding rounds from 6 investors. The company received regulatory approval in Israel for its next-generation XSense Cryoablation System for breast cancer and other indications in September 2025.

Business overview

IceCure Medical is a Health Tech & Life Sciences company focused on transforming healthcare through advanced minimally invasive cryoablation for benign and malignant tumors. Its core technology, the FDA-cleared and CE-marked ProSense® System, utilizes liquid nitrogen to destroy tumors by freezing them, offering an alternative to surgical removal. The company serves the women's health and interventional oncology markets, with its products used in general surgery, thoracic surgery, gynecology, oncology, proctology, and urology across various global markets including Europe, East Asia, Brazil, and India.

Strategic signal

In October 2025, IceCure Medical received FDA Marketing Authorization for its ProSense® Cryoablation system for the treatment of low-risk breast cancer in women aged 70 and above. This marks a significant regulatory milestone, positioning ProSense as the first and only medical device to receive such authorization, and signals a major advancement in providing minimally invasive care for this patient demographic.

Company Intelligence Q&A

What was a significant regulatory achievement for IceCure Medical in late 2025?
In October 2025, IceCure Medical received FDA Marketing Authorization for its ProSense® Cryoablation system for the treatment of low-risk breast cancer in women aged 70 and above, making it the first and only medical device with this specific authorization.
What new patent was granted to IceCure Medical in September 2025?
In September 2025, IceCure Medical was granted a Notice of Allowance for a U.S. Patent for its next-generation XSense™ Cryoprobes, indicating progress in its cryoablation technology.
What were the findings from the independent THERMAC Trial featuring IceCure's ProSense® in breast cancer, published in September 2025?
Two new publications from the independent THERMAC Trial in September 2025 found that 95% of patients were satisfied with thermal ablation using IceCure's ProSense®, which also achieved the highest complete ablation rate.
What were the results of IceCure's ICE3 clinical trial published in September 2024?
In September 2024, the 5-year trial results of IceCure's ICE3 study were published in the Annals of Surgical Oncology Journal, demonstrating a 96.3% recurrence-free rate for early-stage, low-risk breast cancer patients treated with ProSense® cryoablation without excision.
When did IceCure Medical receive regulatory approval for its ProSense® Cryoablation System in Brazil?
In September 2023, IceCure Medical's ProSense® Cryoablation System received regulatory approval in Brazil, expanding its market reach.

External links